SEARCH · PubMed Health

Results for “Cross Protection”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 163 records · Page 9Linked to original sources

PubMed1995

HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques.

Rhesus macaques were immunized with attenuated vaccinia or canarypox human immunodeficiency virus type 1 (HIV-1) recombinants and boosted with HIV-1 protein subunits formulated in alum. Following challenge with HIV-2SBL6669, three out of eight immunized macaques resisted infection for six months and another exhibited significantly delayed infection, whereas all three naive controls became infected. Immunizations elicited both humoral and cellular immune responses; however, no clear correlates of protection were discerned. Although more extensive studies are now called for, this first demonstration of cross-protection between HIV-1 and -2 suggests that viral variability may not be an insurmountable problem in the design of a global AIDS vaccine.

AIDS Vaccines↗

PubMed2001

A cross-protection experiment in pigs vaccinated with Haemophilus parasuis serovars 2 and 5 bacterins, and evaluation of a bivalent vaccine under laboratory and field conditions.

Cross-protection between Haemophilus parasuis serovars 2 and 5 was examined in pigs using a bacterin based vaccine, and subsequently the safety and efficacy of a bivalent vaccine were evaluated. Upon intratracheal challenge of a serovar 2 or 5 strain, pigs immunized with a monovalent vaccine were protected against challenge with a homologous serovar strain, but not with a heterologous serovar strain. Immunization with a bivalent vaccine containing both serovars 2 and 5 bacterins conferred protection in pigs against lethal challenge with each of the serovar strains. A total of 86 pigs from two SPF herds were injected with the bivalent vaccine intramuscularly twice at a four-week interval. No adverse reactions following the vaccination were observed. On day 7 after the second vaccination, vaccinated and non-vaccinated control pigs from herd A were transferred to herd B, where Glasser's disease had broken out. Pigs in the control group developed clinical signs of the disease, and 6 of 8 (75%) pigs died until slaughter, in contrast with only 4 of 46 (9%) pigs in the vaccinated group. In herd C, where there was no outbreak of Glasser's disease, complement fixation antibody titer was raised only in the vaccinated group. A challenge experiment on days 20 and 79 after the second vaccination showed that only the vaccinated pigs were protected. From these findings, the safety and efficacy of the bivalent vaccine were confirmed under laboratory and field conditions.

Animals↗

PubMed1992

Cross protection studies on Bordetella bronchiseptica in mice using an intracerebral challenge model.

Protective activities of heat-inactivated (60 degrees C for 30 min) merthiolate preserved Bordetella bronchiseptica and B. pertussis bacterins were compared in intraperitoneally immunized mice challenged intracerebrally (i.p./i.c.) or intraperitoneally (i.p./i.p.). In the i.p./i.c. assay (Kendrick test), a B. pertussis bacterin protected mice against challenge with B. pertussis 18-323, as well as against phase I cytotoxic and non-cytotoxic strains of B. bronchiseptica. A B. bronchiseptica bacterin, prepared from a phase I cytotoxic strain, gave protection against two phase I B. bronchiseptica strains, irrespective of their cytotoxin-production. A non-cytotoxic phase I strain of B. bronchiseptica elicited protection against the homologous strain only. Neither cytotoxic nor non-cytotoxic B. bronchiseptica strains protected mice challenged with B. pertussis 18-323. Vaccines prepared from phase III strains of B. bronchiseptica were not protective at all against any of the challenge strains. No such differences in the protective activities of the bacterins could be detected by the i.p./i.p. method. They seem to cross-protect equally well. The results indicate that the Kendrick test may be useful in testing potency of different B. bronchiseptica bacterins.

Animals↗

PubMed1989

Avian infectious bronchitis: cross-protection studies using different Australian subtypes.

The cross-immunity of vaccinated chickens after challenge with some Australian infectious bronchitis viruses was assessed by humoral antibody responses and by ciliary activity in tracheal rings of vaccinated chickens following challenge. Four viruses were used for vaccination: Vac 3, Vac 4, both current infectious bronchitis vaccine viruses, and Q1/76 and N2/62. IBV N1/62 (synonym T0 and infectious bronchitis virus N9/74 (synonym Appin) were used to challenge the vaccinated chickens. Results showed a lack of correlation between humoral antibody levels and protection. Cross-immunity was found after vaccination with each subtype, but was lower for Vac 3 and Vac 4 than for Q1/76 and N2/62.

Animals↗

PubMed2006

Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets.

Ferrets were immunized with two 7- mu g doses of hemagglutinin from inactivated whole-virus vaccines containing the hemagglutinin gene of A/Duck/Singapore/3/97(H5N3) then inoculated with a lethal dose of A/Vietnam/1203/04(H5N1) (Viet/1203/04). Serum samples did not react with Viet/1203/04 in hemagglutination-inhibition (HI) or virus-neutralization (VN) tests. All vaccinated ferrets survived the challenge, whereas all mock-immunized ferrets died. Immunized ferrets had significantly lower virus titers in the upper respiratory tract and less-severe disease. Vaccine generated from antigenically different H5 virus protects against infection by a highly pathogenic H5 strain. Neither HI nor VN testing provides correlates of cross-protection in ferrets.

Animals↗

PubMed1991

Protection against tetrodotoxin and saxitoxin intoxication by a cross-protective rabbit anti-tetrodotoxin antiserum.

A tetrodotoxin-formaldehyde-keyhole limpet hemocyanin conjugate was used to immunize a rabbit for the production of anti-toxin antiserum. The antiserum cross-reacted against both tetrodotoxin (TTX) and saxitoxin (STX), and in a quantitative in vitro assay was able to protect cells in a dose-dependent manner from the effects of either TTX or STX. The antiserum was also able to passively protect mice challenged in vivo with either toxin. Hybridomas producing monoclonal antibodies against toxin were obtained from the spleens of mice immunized with the same conjugate.

Animals↗

PubMedDate not supplied

Cross-protection test of an avian poxvirus isolated from houbara bustards.

An avian poxvirus was isolated previously from the houbara bustard (Chlamydotis undulata). We carried out a cross-protection test on 66 captive-bred canaries. Thirty-five canaries were vaccinated with a commercial canary poxvirus (CP) vaccine. Three weeks later all 66 birds were assigned randomly to six different groups: group Ia (n = 14) was vaccinated and challenged with houbara bustard poxvirus (HP) strain; group Ib (n = 13) was vaccinated and challenged with a CP strain; group Ic (n = 7) was vaccinated and not inoculated; group IIa (n = 14) was nonvaccinated and challenged with HP strain; group IIb (n = 11) was nonvaccinated and challenged with a CP strain; and group IIc (n = 7) was not vaccinated and not challenged. Vaccinated groups (Ia, Ib, Ic) had no losses and remained healthy. All of the birds (100%) in group IIb died within 10 days, and 10 birds (71.4%) of group IIa died within 20 days. The nonvaccinated control group (IIc) remained healthy. Poxvirus was isolated from the liver, digestive tract, lungs, and inoculation lesions of nonvaccinated dead CP- and HP-challenged birds. Secondary bacterial infections were higher among nonvaccinated HP-challenged birds (85.7%) than in nonvaccinated CP-challenged birds (25%). The results of this experiment reveal a degree of immunogenic relatedness between CP and HP strain and support the recommendation that houbara bustards be vaccinated with a CP vaccine.

Animals↗

PubMed1999

Foetal cross-protection experiments between type 1 and type 2 bovine viral diarrhoea virus in pregnant ewes.

A flock of 82 non-pregnant ewes was split into three immunisation groups and given an intranasal dose of either cell culture medium, or a type 1 or a type 2 bovine viral diarrhoea virus (BVDV-1 or BVDV-2). Two months later the flock was reconstituted and after a further three weeks, the ewes were bred to pestivirus negative rams after synchronisation of oestrus using progesterone sponges. Fifty-five ewes were segregated into three challenge groups, each of which comprised ewes from different immunisation groups. At 7 weeks gestation, one challenge group was given an intranasal dose of cell culture medium, whilst the other two were given intranasal doses of either BVDV-1 or BVDV-2, using the same inocula as for the immunisations. Three weeks later, the ewes were killed and their foetuses tested for the presence of BVDV-1 and BVDV-2. The results showed that immunisation of six ewes without subsequent challenge did not lead to infection of any of their 11 foetuses. Challenge with BVDV-1 or BVDV-2 in the absence of immunisation lead to 15 out of 15 or 11 out of 14 foetuses becoming infected, respectively. Immunisation with the homologous virus to that used for challenge resulted in complete protection of 32 foetuses from 15 ewes. Heterologous protection was one way. All 12 foetuses from ewes immunised with BVDV-1 were protected from challenge with BVDV-2, whereas 18 foetuses from ewes immunised with BVDV-2 were all infected after challenge with BVDV-1. This provides evidence that a recent exposure to infection with one pestivirus does not necessarily induce foetal protection against another. The one-way result suggests that factors other than antigenic differences are involved in cross-protection.

Administration, Intranasal↗

PubMed1996

Infection and cross-protection studies of winter dysentery and calf diarrhea bovine coronavirus strains in colostrum-deprived and gnotobiotic calves.

OBJECTIVE: To investigate in vitro antigenic relations, in vivo cross-protection, and isotype antibody responses to a winter dysentery (WD) and calf diarrhea strain of bovine coronavirus (BCV). DESIGN AND ANIMALS: Gnotobiotic and colostrum-deprived calves were inoculated oronasally with a WD (DBA) or a calf diarrhea (DB2) BCV, and were challenge exposed with the heterologous BCV. PROCEDURE: Nasal swab and feces specimens and blood samples were collected. Fecal and nasal specimens were assayed for BCV shedding by antigen-capture ELISA or immune electron microscopy. Bovine coronavirus antigens were detected in nasal epithelial cells by immunofluorescence. Antibody titers to BCV in serum were assayed by virus neutralization (VN), and BCV antibody isotype titers in feces and sera were quantitated by ELISA. RESULTS: All calves developed diarrhea and shed BCV nasally and in feces, then recovered and were protected from BCV-associated diarrhea after challenge exposure with the heterologous BCV. After challenge exposure with either strain, fecal shedding of DBA was detected in 1 of 4 calves and nasal shedding of DB2 was detected in 2 of 4 calves. Immunoglobulin M was the principal coproantibody to BCV early, followed predominantly by IgA. Immunoglobulin G1 coproantibody titers to BCV were low, but increased after challenge exposure. Immunoglobulin G1 antibodies were predominant in serum. After challenge exposure, all serum antibody isotype titers increased except IgG2. The VN antibody responses paralleled serum IgG1 antibody responses. CONCLUSIONS AND CLINICAL RELEVANCE: Immunoglobulin A coproantibodies at challenge exposure were associated with protection against diarrhea. Nasal shedding of BCV after challenge exposure confirmed field data documenting reinfection of the respiratory tract of cattle, suggesting that, in closed herds, respiratory tract infections constitute a source of BCV transmission to cows (WD) or young calves.

Animals↗

PubMed1968

Cross-protection against Salmonella enteritidis infection in mice.

Mice were vaccinated with six strains of Salmonella and two strains of Escherichia coli, as well as with Pseudomonas aeruginosa, Proteus vulgaris, and Serratia marcescens. The amount of in vivo growth of each organism was followed by viable counting techniques on organ homogenates. The vaccinated mice, along with unvaccinated controls, were challenged intravenously with 1,000 ld(50) of a streptomycin-resistant strain of Salmonella enteritidis. The ability of the vaccine to protect the mice against virulent challenge correlated with the ability of the strain to establish a persisting population in the liver and spleen. Enumeration of the liver and spleen populations in the challenged mice revealed that extensive growth of S. enteritidis occurred in animals which showed "protection," as assessed by progressive mortality data. No evidence was obtained for a major role of humoral factors in the cross-protection against intravenous S. enteritidis challenge.

Animals↗

PubMed1981

Nature of the cross-protective antigen in subcellular vaccines of Streptococcus pneumoniae.

Studies have been carried out to investigate the nature of the antigen present in subcellular extracts of a rough strain of Streptococcus pneumoniae A662b which has been shown to confer protection in mice against challenge with smooth, virulent organisms of the homologous and heterologous serotypes. The finding that whole, heat-killed cells were also capable of immunizing mice against challenge with organisms of heterologous serotypes suggests that the immunogen is present on the surface of the rough pneumococcal cell. Ribosomes purified by sucrose gradient centrifugation were not protective, but material recovered in the pellet retained activity. Subcellular extracts prepared from spheroplasts with a partial absence of cell wall showed decreased protective capacity, and extracts prepared from wall-deficient protoplasts were not protective. Crude cell walls evidenced cross-serotype protection, but purified walls did not protect. These results are interpreted as suggesting that the active moiety in the subcellular vaccine is present on the surface of rough pneumococci and is either a wall antigen that must be part of a larger macromolecular complex to be immunogenic, or a substance associated with the cell wall that is present in crude, but not purified, cell wall fractions.

Animals↗

PubMed2001

Adaptive and cross-protective responses of Pseudomonas sp. DJ-12 to several aromatics and other stress shocks.

Pseudomonas sp. DJ-12 cells were subjected to mild treatments of stress such as exposure to biphenyl, 4-chlorobiphenyl (4CB), 4-hydroxybenzoate (4HBA), ethanol, and heat, and then were examined for production of stress-shock proteins and morphological changes. The adapted cells were then subjected to lethal stress conditions such as 200 mm 4CB, 100 mm biphenyl, 10 mm 4HBA, 20% ethanol, and 46 degrees C to examine crossly protective responses to the stresses. Several stress-shock proteins including DnaK and GroEL were newly synthesized in the adapted cells. Some of them were commonly produced by those stresses separately treated. The cells treated with these aromatic hydrocarbons showed destructive openings on the cell envelopes. On the other hand, those cells treated with ethanol or heat displayed irregular rod shapes with wrinkled surfaces. The adapted cells to each stress under sublethal conditions exhibited increased resistance to the same stress of lethal conditions. The cells adapted with 5 mm 4HBA showed greater protection for survival than those adapted by other stresses. In addition, those adapted cells showed increased resistance to other stresses as a cross-protection phenomenon. The cells adapted to 42 degrees C exhibited markedly increased resistance to the lethal stresses of 46 degrees C as well as to 20% ethanol.

Adaptation, Physiological↗

PubMed2000

Tobacco mosaic virus replicase-mediated cross-protection: contributions of RNA and protein-derived mechanisms.

Specific sequences of the tobacco mosaic virus (TMV) RNA-dependent RNA-polymerase (RdRp) gene were investigated for their ability to confer cross-protection. Nine overlapping segments ranging from 713 to 1070 nucleotides in length and covering the methyltransferase, helicase, and polymerase (POL) domains of the TMV RdRp open reading frame were systemically expressed in Nicotiana benthamiana using a potato X virus (PVX) vector [Chapman, S., Kavanagh, T., and Baulcombe, D. C. (1992). Plant J., 1, 549-557]. PVX-infected plants were subsequently challenge inoculated with 10 microg of wild-type TMV and monitored for TMV accumulation. Mock inoculated plants and plants preinfected with the unmodified PVX vector rapidly accumulated high levels of challenge virus. In contrast, plants preinfected with PVX vectors expressing segments of the TMV RdRp open reading frame displayed either high or low levels of protection. High protection levels were observed for PVX constructs expressing segments of the TMV POL domain, whereas low protection levels were observed for PVX constructs expressing segments covering the methyltransferase and helicase domains. Frameshift mutations that blocked protein expression from RdRp segments disrupted only the high levels of protection derived from POL segments and not the low levels derived from the other segments. However, all RdRp segments conferred similarly high levels of protection against a TMV construct with restricted local movement. Thus both RNA and protein sequences in conjunction with the speed of the infecting challenge virus can affect the protection derived from the TMV RdRp gene.

Frameshift Mutation↗

PubMed1984

Differences in cross-protection in rats immunized with the B subunits of cholera toxin and Escherichia coli heat-labile toxin.

Although cholera toxin (CT), Escherichia coli heat-labile toxin (LT), and their B subunits are known to be immunologically related, the ability of each to raise an antitoxin response that provides equally strong cross-protection against active challenge with pure heterologous toxin has not been examined previously. We immunized rats with pure preparations of the B subunits of human LT, porcine LT, and CT. Immunization with either of the LT B subunits raised greater than or equal to fourfold increases in specific mucosal immunoglobulin A antitoxin titers to homologous and heterologous LT and CT B subunits, thereby providing strong protection against active challenge in ligated ileal loops with all three respective holotoxins and with a viable LT-producing E. coli strain. In contrast, immunization with the CT B subunit raised a greater than or equal to fourfold increase in antitoxin titers only to itself and provided strong protection only against challenge with the CT holotoxin. Conjugation of the CT B subunit with the E. coli heat-stable toxin by the carbodiimide reaction yielded a cross-linked immunogen with equal antigenicity for both components; immunization with this conjugate raised greater than or equal to fourfold increases in antitoxin titers to both components, but it provided significant protection only against challenge with a viable heat-stable toxin-producing E. coli strain and not to an LT-producing E. coli strain. These observations indicate that immunization with the LT B subunits raises a heterologous antitoxin response that extends to the CT B subunit, thereby providing equally strong protection against LT and CT; however, immunization with the CT B subunit raises principally a homologous antitoxin response, so that this immunogen provides strong protection only against CT.

Animals↗

PubMed1977

Demonstration of cross-protection between Pasteurella multocida type A and Pasteurella haemolytica, serotype 1.

Mice immunized with the potassium thiocyanate extract of Pasteurella haemolytica, serotype 1, were found to resist a challenge infection of P. multocida type A, thus demonstrating cross-protection. This finding was further supported by the finding that an antiserum directed against the potassium thiocyanate extract of P. haemolytica was bactericidal to P. multocida and vice versa.

Animals↗

PubMed1986

Immunity to tapeworms: intraspecific cross-protective interactions between Hymenolepis citelli, H. diminuta and H. microstoma in mice.

Interactions between tapeworm species in a single host offer intriguing opportunities for immunological studies that attempt to identify the mechanism(s) underlying protection against cestode infections. Mice that are immunized against Hymenolepis citelli infections were shown to be refractory to subsequent H. diminuta challenge infections. The reciprocity of the response was also demonstrated, although the protection recorded for H. diminuta when mice are sensitized with H. citelli is weaker than that observed when mice are primed with H. diminuta against H. citelli challenge. H. citelli was also shown to be expelled simultaneously during the rejection phase of H. diminuta in concurrent infections, indicating the susceptibility of the former tapeworm to the rejection mechanism initiated by the latter. H. microstoma-immunized mice were shown to be strongly protected against heterologous H. citelli challenge. However, mice primed against H. citelli were not as strongly protected against H. microstoma challenge infections: a statistically significant protection was obtained only after a 12-cysticercoid H. citelli primary infection, although a 6-cyst infection did stunt the growth of H. microstoma challenge worms. It is presently suggested that the cross-protective responses observed in the study between H. citelli, H. diminuta and H. microstoma may have emanated from a specific immunological cross-reactivity due to the sharing of similar immunogens.

Animals↗

PubMed2003

Cross-protection between distantly related spotted fever group rickettsiae.

Two excellent C3H/HeN mouse models of spotted fever rickettsioses caused by the distantly related organisms, Rickettsia conorii and Rickettsia australis, were utilized to evaluate the possibility of the stimulation of broad cross-protective immunity. Sublethal infection stimulated complete immunity, that is absence of disease, after challenge with a dose of the heterologous Rickettsia that uniformly killed naïve mice. In contrast, heterologous immune sera did not protect mice against a lethal dose (two LD50) of rickettsiae in the mouse toxicity neutralization assay, the standard method for evaluation of rickettsial vaccine potency. These observations suggest that development of a broadly protective vaccine against spotted fever group (SFG) rickettsiae is feasible, and the results indicate that mouse toxicity neutralization is an inappropriate method for evaluation of candidate vaccines.

Animals↗

PubMed2001

Identification of the hemolysis-associated protein 1 as a cross-protective immunogen of Leptospira interrogans by adenovirus-mediated vaccination.

New vaccine strategies are needed for the prevention of leptospirosis, a widespread human and animal disease caused by pathogenic leptospires. Our previous work determined that a protein leptospiral extract conferred cross-protection in a gerbil model of leptospirosis. The 31- to 34-kDa protein fraction of Leptospira interrogans serovar autumnalis was shown sufficient for this purpose. In the present study, N-terminal sequencing of a 32-kDa fraction and Southern blotting of genomic DNA with corresponding degenerated oligonucleotide probes identified two of its constituents: hemolysis-associated protein 1 (Hap1) and the outer membrane Leptospira protein 1 (OmpL1). Adenovirus-mediated Hap1 vaccination induces significant protection against a virulent heterologous Leptospira challenge in gerbils, whereas a similar OmpL1 construct failed to protect the animals. These data indicate that Hap1 could be a good candidate for developing a new generation of vaccines able to induce broad protection against leptospirosis disease.

Adenoviridae↗